Hypertension Drug Market by Therapy (Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers), Analysis (Pulmonary Hypertension Drugs, Systemic Hypertension Drugs), Type, Distribution - Global Forecast 2024-2030

Hypertension Drug Market by Therapy (Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers), Analysis (Pulmonary Hypertension Drugs, Systemic Hypertension Drugs), Type, Distribution - Global Forecast 2024-2030


The Hypertension Drug Market size was estimated at USD 26.88 billion in 2023 and expected to reach USD 29.20 billion in 2024, at a CAGR 8.73% to reach USD 48.32 billion by 2030.

Global Hypertension Drug Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hypertension Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hypertension Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hypertension Drug Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hypertension Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapy
Alpha Blockers

Angiotensin Converting Enzyme Inhibitor

Angiotensin Receptor Blockers

Beta Blockers Vasodilators

Calcium Channel Blockers

Diuretics

Renin Inhibitors

Analysis
Pulmonary Hypertension Drugs

Systemic Hypertension Drugs

Type
Combination Therapy

Mono Therapy

Distribution
Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hypertension Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hypertension Drug Market?
3. What are the technology trends and regulatory frameworks in the Hypertension Drug Market?
4. What is the market share of the leading vendors in the Hypertension Drug Market?
5. Which modes and strategic moves are suitable for entering the Hypertension Drug Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hypertension Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in awareness related to complications associated with hypertension
5.1.1.2. Increasing prevalence of hypertension coupled with geriatric population
5.1.1.3. Advances in pharmacologic treatment of hypertension
5.1.2. Restraints
5.1.2.1. Unavailability of hypertension drugs in remote areas
5.1.3. Opportunities
5.1.3.1. Growing initiatives by private and government organizations for R&D
5.1.3.2. Increasing focus on development of new drugs
5.1.4. Challenges
5.1.4.1. Increased concern of side-effects of treatment options
5.1.4.2. Rising number of alternate generic drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hypertension Drug Market, by Therapy
6.1. Introduction
6.2. Alpha Blockers
6.3. Angiotensin Converting Enzyme Inhibitor
6.4. Angiotensin Receptor Blockers
6.5. Beta Blockers Vasodilators
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors
7. Hypertension Drug Market, by Analysis
7.1. Introduction
7.2. Pulmonary Hypertension Drugs
7.3. Systemic Hypertension Drugs
8. Hypertension Drug Market, by Type
8.1. Introduction
8.2. Combination Therapy
8.3. Mono Therapy
9. Hypertension Drug Market, by Distribution
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Hypertension Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Hypertension Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.
10. South Korea
11.
11. Taiwan
11.
12. Thailand
11.
13. Vietnam
12. Europe, Middle East & Africa Hypertension Drug Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.
10. Nigeria
12.
11. Norway
12.
12. Poland
12.
13. Qatar
12.
14. Russia
12.
15. Saudi Arabia
12.
16. South Africa
12.
17. Spain
12.
18. Sweden
12.
19. Switzerland
12.
20. Turkey
12.
21. United Arab Emirates
12.
22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AstraZeneca PLC
14.1.2. Bayer AG
14.1.3. Boehringer Ingelheim International GmbH
14.1.4. Daiichi Sankyo Company, Limited
14.1.5. F. Hoffmann-La Roche Ltd.
14.1.6. Gilead Sciences, Inc.
14.1.7. GlaxoSmithKline PLC
14.1.8. Johnson & Johnson Services, Inc.
14.1.9. Lupin Limited
14.1.
10. Merck KGaA
14.1.
11. Novartis AG
14.1.
12. Pfizer Inc.
14.1.
13. Sanofi S.A.
14.1.
14. Sun Pharmaceutical Industries Limited
14.1.
15. Takeda Pharmaceutical Company Limited
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. HYPERTENSION DRUG MARKET RESEARCH PROCESS
FIGURE 2. HYPERTENSION DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. HYPERTENSION DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HYPERTENSION DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HYPERTENSION DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HYPERTENSION DRUG MARKET DYNAMICS
FIGURE 7. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 8. HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2030 (%)
FIGURE 10. HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 12. HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 14. HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES HYPERTENSION DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. HYPERTENSION DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. HYPERTENSION DRUG MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings